{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T23:14:22Z","timestamp":1790378062897,"version":"4.1.0"},"reference-count":72,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This chapter explores the complex and controversial path of MDMA-assisted therapy (MDMA-AT) for treating post-traumatic stress disorder (PTSD) and other behavioral disorders. It covers MDMA\u2019s history from research to recreation to medicine, the pivotal trials, and the challenges faced by researchers. Despite recent setbacks for the clinical application of MDMA, the chapter argues that it holds potential for transforming psychiatry and discusses the uncertain future amidst ongoing debates over ethics, methodology, and political influence.<\/jats:p>","DOI":"10.1017\/s1092852925000057","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T06:56:02Z","timestamp":1738220162000},"source":"Crossref","is-referenced-by-count":7,"title":["MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders"],"prefix":"10.1017","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9567-9997","authenticated-orcid":false,"given":"Steve","family":"O\u2019Brien","sequence":"first","affiliation":[{"name":"Imperial College London"},{"name":"Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nutt","sequence":"additional","affiliation":[{"name":"Imperial College London"},{"name":"Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"S1092852925000057_r7","unstructured":"7. MDA. Misuse of Drugs Act 1971. London; 1971."},{"key":"S1092852925000057_r25","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0174-5"},{"key":"S1092852925000057_r23","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200404000-00009"},{"key":"S1092852925000057_r41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1075-9"},{"key":"S1092852925000057_r1","first-page":"917","article-title":"The pharmacology and toxicology of \u201cecstasy\u201d (MDMA) and related drugs","volume":"165","author":"Kalant","year":"2001","journal-title":"CMAJ"},{"key":"S1092852925000057_r18","unstructured":"18. UN. Statistical Annex. P. o. d. u. i. t. g. p. r. a. g. estimates, UNODC; 2024."},{"key":"S1092852925000057_r67","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-024-01622-3"},{"key":"S1092852925000057_r2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.02948.x"},{"key":"S1092852925000057_r31","doi-asserted-by":"publisher","DOI":"10.1093\/jat\/33.8.439"},{"key":"S1092852925000057_r38","doi-asserted-by":"publisher","DOI":"10.1177\/0269881121991792"},{"key":"S1092852925000057_r68","unstructured":"68. Stone, W . Trouble for ecstasy? What MDMA\u2019s FDA setback could mean for psychedelics; 2024."},{"key":"S1092852925000057_r40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4"},{"key":"S1092852925000057_r29","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15348"},{"key":"S1092852925000057_r8","unstructured":"8. MDA. The Misuse of Drugs Act 1971 (Modification) Order 1977; 1977."},{"key":"S1092852925000057_r13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1074501"},{"key":"S1092852925000057_r50","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-019-05249-5"},{"key":"S1092852925000057_r37","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4"},{"key":"S1092852925000057_r49","doi-asserted-by":"publisher","DOI":"10.1080\/17470910802649470"},{"key":"S1092852925000057_r39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01336-3"},{"key":"S1092852925000057_r10","unstructured":"10. Measham, A. , Parker, (2001). Dancing on drugs: risk, health and hedonism in the British Club Scene, free association books: 108."},{"key":"S1092852925000057_r32","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4682-7-34"},{"key":"S1092852925000057_r60","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.114.152751"},{"key":"S1092852925000057_r46","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.601519"},{"key":"S1092852925000057_r14","volume-title":"The history of MDMA","year":"2023"},{"key":"S1092852925000057_r57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61462-6"},{"key":"S1092852925000057_r17","unstructured":"17. UN. Annual prevalence of the use of drugs by region and globally; 2018."},{"key":"S1092852925000057_r51","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117691569"},{"key":"S1092852925000057_r16","unstructured":"16. Buchanan, D. Leah Betts died 20 years ago and we still can\u2019t be honest about drugs; 2015"},{"key":"S1092852925000057_r22","doi-asserted-by":"publisher","DOI":"10.1177\/2050324519898963"},{"key":"S1092852925000057_r54","doi-asserted-by":"publisher","DOI":"10.1159\/000026669"},{"key":"S1092852925000057_r42","doi-asserted-by":"publisher","DOI":"10.1177\/070674371405900902"},{"key":"S1092852925000057_r56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60464-4"},{"key":"S1092852925000057_r43","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(00)00130-5"},{"key":"S1092852925000057_r4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00138"},{"key":"S1092852925000057_r35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01385-8"},{"key":"S1092852925000057_r64","unstructured":"64. Collis, H . Ukrainian MP tells MEPs country should be test bed for psychedelics; 2023."},{"key":"S1092852925000057_r20","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14209"},{"key":"S1092852925000057_r34","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145713001405"},{"key":"S1092852925000057_r26","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.8b00155"},{"key":"S1092852925000057_r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2015.08.016"},{"key":"S1092852925000057_r12","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3530-c2"},{"key":"S1092852925000057_r24","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-019-0569-3"},{"key":"S1092852925000057_r69","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-022-06123-7"},{"key":"S1092852925000057_r65","unstructured":"65. UPRA. Ukrainian Psychedelic Research Association; 2024. https:\/\/www.upra.org.ua\/en."},{"key":"S1092852925000057_r5","unstructured":"5. Riederer, R . The Rebranding of MDMA; 2023."},{"key":"S1092852925000057_r19","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-016-0078-x"},{"key":"S1092852925000057_r71","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05548-2"},{"key":"S1092852925000057_r63","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116663120"},{"key":"S1092852925000057_r44","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/141396"},{"key":"S1092852925000057_r47","doi-asserted-by":"publisher","DOI":"10.1159\/000253551"},{"key":"S1092852925000057_r33","first-page":"381","article-title":"MDMA and the brain: a short review on the role of neurotransmitters in neurotoxicity","volume":"11","author":"Mustafa","year":"2020","journal-title":"Basic Clin Neurosci"},{"key":"S1092852925000057_r53","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301415"},{"key":"S1092852925000057_r58","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119841569"},{"key":"S1092852925000057_r36","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118806297"},{"key":"S1092852925000057_r70","first-page":"1","article-title":"Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","author":"Mithoefer","year":"2024","journal-title":"Psychopharmacology"},{"key":"S1092852925000057_r59","first-page":"107868","article-title":"Australian and New Zealand drug harm rankings: a cross-national comparison","volume":"208","author":"Crossin","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"S1092852925000057_r61","unstructured":"61. Netzer, O , Magal, N , Stern, Y , et al. (2024). Trauma under psychedelics: MDMA shows protective effects during the peritraumatic period. bioRxiv: 2024.2003.2028.587237."},{"key":"S1092852925000057_r9","unstructured":"9. Fisher, M . Night lives: Reducing drug-related harm in the night time economy; 2018."},{"key":"S1092852925000057_r62","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2021.698655"},{"key":"S1092852925000057_r27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.08.003"},{"key":"S1092852925000057_r6","first-page":"30210","article-title":"Schedules of controlled substances. Proposed placement of 3, 4-methylenedioxymethamphetamine into Schedule I","volume":"49","author":"Mullen","year":"1984","journal-title":"Fed Regist"},{"key":"S1092852925000057_r15","doi-asserted-by":"publisher","DOI":"10.4161\/23328940.2014.977182"},{"key":"S1092852925000057_r28","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-0038-z"},{"key":"S1092852925000057_r30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706688"},{"key":"S1092852925000057_r45","first-page":"55","article-title":"How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions","volume":"21","author":"Sapolsky","year":"2000","journal-title":"Endocr Rev"},{"key":"S1092852925000057_r11","unstructured":"11. Measham, F . \u20183\u2019, in Drug Science and British Drug Policy: Critical Analysis of the Misuse of Drugs Act 1971. Waterside Press; 2022."},{"key":"S1092852925000057_r21","unstructured":"21. Berry, J . Remembering the Great British Mephedrone Craze. Vice; 2019."},{"key":"S1092852925000057_r66","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1606472"},{"key":"S1092852925000057_r72","first-page":"1","article-title":"Retraction note: long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials","author":"Jerome","year":"2024","journal-title":"Psychopharmacology"},{"key":"S1092852925000057_r48","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0000000000000060"},{"key":"S1092852925000057_r3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2006.01511.x"},{"key":"S1092852925000057_r55","doi-asserted-by":"publisher","DOI":"10.1177\/0269881112464827"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852925000057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:45:26Z","timestamp":1759848326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852925000057\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"alternative-id":["S1092852925000057"],"URL":"https:\/\/doi.org\/10.1017\/s1092852925000057","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"e15"}}